Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study

利比韦林 医学 打开标签 替诺福韦 杜鲁特格拉维尔 恩曲他滨 人类免疫缺陷病毒(HIV) 内科学 临床试验 病毒载量 抗逆转录病毒疗法 病毒学
作者
Hans Jaeger,Edgar T. Overton,Gary Richmond,Giuliano Rizzardini,Jaime Andrade‐Villanueva,Rosie Mngqibisa,Antonio Ocampo Hermida,Anders Thalme,Elena Belonosova,Faïza Ajana,Paul Benn,Yuanyuan Wang,Krischan J Hudson,Carlos Martín Español,Susan L. Ford,Herta Crauwels,David A. Margolis,Christine L. Talarico,Kimberly Y. Smith,Veerle Van Eygen
出处
期刊:The Lancet HIV [Elsevier BV]
卷期号:8 (11): e679-e689 被引量:98
标识
DOI:10.1016/s2352-3018(21)00185-5
摘要

Background Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy. The ATLAS-2M week 48 results showed non-inferiority of long-acting cabotegravir and rilpivirine administered every 8 weeks compared with that of every 4 weeks. In this study, we report the efficacy, safety, and tolerability results from the week 96 analysis. Methods ATLAS-2M is a randomised, multicentre, open-label, phase 3b, non-inferiority trial conducted in 13 countries, evaluating the safety and efficacy of maintenance treatment with intramuscular injections of long-acting cabotegravir and rilpivirine, administered every 8 weeks versus every 4 weeks, to people living with HIV-1. Virologically suppressed adults with HIV-1, either already receiving intramuscular long-acting cabotegravir and rilpivirine every 4 weeks (ie, ATLAS study rollover participants) or oral standard of care, were randomly assigned (1:1), in an unblinded fashion, to receive either intramuscular long-acting cabotegravir (600 mg) and rilpivirine (900 mg) every 8 weeks (ie, the every 8-week dosing group) or intramuscular long-acting cabotegravir (400 mg) and rilpivirine (600 mg) every 4 weeks (ie, the every 4-week dosing group). Randomisation was generated using the GlaxoSmithKline-validated randomisation software RANDALL NG (version 1.3.3). The primary endpoint at week 48 was the proportion of participants with plasma HIV-1 RNA measurements of 50 copies per mL or more (ie, the US Food and Drug Administration [FDA] Snapshot algorithm), which has been published previously. Here, we present the week 96 results: the proportion of participants with plasma HIV-1 RNA measurements of less than 50 copies per mL (FDA Snapshot algorithm), with a non-inferiority margin of −10%; the proportion of participants with plasma HIV-1 RNA measurements of 50 copies per mL or more (FDA Snapshot algorithm), with a non-inferiority margin of 4%; the proportion of participants with protocol-defined confirmed virological failure (ie, two consecutive plasma HIV-1 RNA measurements ≥200 copies per mL); safety; pharmacokinetics; and tolerability. This study is registered with ClinicalTrials.gov, number NCT03299049, and is currently ongoing. Findings Between Oct 27, 2017, and May 31, 2018, a total of 1149 participants were screened; of whom, 1049 (91%) were randomly assigned and 1045 (91%) initiated treatment (522 in the every 8-week dosing group and 523 in the every 4-week dosing group). The median age was 42 years (IQR 34–50). 280 (27%) of 1045 participants were assigned female at birth and 764 (73%) were white. At week 96 (FDA Snapshot algorithm), 11 (2%) of 522 participants in the every 8-week dosing group and six (1%) of 523 in the every 4-week dosing group had an HIV-1 RNA measurement of 50 copies per mL or more, with an adjusted treatment difference of 1·0 (95% CI −0·6 to 2·5), meeting the prespecified non-inferiority threshold of 4%; 475 (91%) of 522 participants in the every 8-week dosing group and 472 (90%) of 523 in the every 4-week dosing group maintained an HIV-1 RNA measurement of less than 50 copies per mL, with an adjusted treatment difference of 0·8 (95% CI −2·8 to 4·3), which met the prespecified non-inferiority threshold of −10%. One participant in the every 8-week dosing group met the confirmed virological failure criterion since the week 48 analysis at week 88, resulting in a total of nine participants in the every 8-week dosing group and two in the every 4-week dosing group having confirmed virological failure. No new safety signals were identified, and no treatment-related deaths occurred. Injection site reactions were the most common adverse event, occurring in 412 (79%) of 522 participants in the every 8-week dosing group and 400 (76%) of 523 in the every 4-week dosing group. Most injection site reactions were grade 1 or 2 (7453 [99%] of 7557 in both groups), with a median duration of 3 days (IQR 2–5). Interpretation Long-acting cabotegravir and rilpivirine dosed every 8 weeks had non-inferior efficacy compared with that of every 4 weeks through the 96-week analysis, with both regimens maintaining high levels of virological suppression. These results show the durable safety, efficacy, and acceptability of dosing long-acting cabotegravir and rilpivirine monthly and every 2 months as maintenance therapy for people living with HIV-1. Funding ViiV Healthcare and Janssen Research & Development.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
陈昊完成签到,获得积分10
6秒前
7秒前
tian发布了新的文献求助10
9秒前
12秒前
12秒前
龙舞星完成签到,获得积分10
13秒前
14秒前
王涉发布了新的文献求助10
16秒前
普鲁卡因发布了新的文献求助10
17秒前
量子星尘发布了新的文献求助10
19秒前
柚子完成签到,获得积分10
23秒前
24秒前
马儿饿了要吃草完成签到,获得积分10
24秒前
26秒前
sudor123456完成签到,获得积分10
31秒前
NXK发布了新的文献求助10
31秒前
打打应助普鲁卡因采纳,获得10
34秒前
36秒前
lii完成签到,获得积分10
36秒前
jiaolulu发布了新的文献求助10
42秒前
个性惜蕊完成签到,获得积分10
42秒前
45秒前
轩辕书白完成签到,获得积分10
46秒前
qinzhikai完成签到,获得积分10
50秒前
天真的冬瓜完成签到,获得积分10
51秒前
小溜溜完成签到 ,获得积分10
52秒前
普鲁卡因发布了新的文献求助10
53秒前
tian发布了新的文献求助10
54秒前
桃花源的瓶起子完成签到 ,获得积分10
58秒前
平凡世界完成签到 ,获得积分10
59秒前
YYLLTX完成签到,获得积分10
1分钟前
畅快山兰完成签到 ,获得积分10
1分钟前
gaoxiaogao完成签到,获得积分10
1分钟前
舒适怀寒完成签到 ,获得积分10
1分钟前
shenglll完成签到 ,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
普鲁卡因发布了新的文献求助10
1分钟前
Liang完成签到,获得积分10
1分钟前
爱思考的小笨笨完成签到,获得积分10
1分钟前
123456完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038112
求助须知:如何正确求助?哪些是违规求助? 3575788
关于积分的说明 11373801
捐赠科研通 3305604
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022